Janssen-Cilag is ranked second in the “Best Pharmaceutical Companies” 2020 ranking in Germany in the category of research-based companies that lead the world in terms of sales and also wins the “Golden Tablet” 2020 award for innovation and sustainability from the Urologists. Janssen-Cialg’s most recent innovation in the field of urology is Erleada® (prostate cancer) with the extension of approval for metastatic hormone-sensitive prostate cancer.
Janssen-Cilag – Award for Innovation and Sustainability
In the health industry, the Pharma Trend Image & Innovation Award is one of the annual highlights with the award of the specialist doctor-specific award “The Golden Tablet“. The “The Golden Tablet” award of the urologists went to Janssen-Cilag in 2020 with 40% of the votes. Thanks to the many innovations (63%), the competence of the sales force (48%), the range of training and further education (45%) and the quality of the products (40%), as well as the research activities and the large product pipeline (25%), Janssen-Cilag earned the award for innovation and sustainability “The Golden Tablet” from the urologists in 2020.
In addition, the urologists voted the drug Erleada® (prostate cancer) into first place for the award “The most innovative product”. Erleada® did not receive the extension of approval for metastatic hormone-sensitive prostate cancer until the beginning of 2020.
In recent years, Janssen has become particularly well known for developing products and therapies in fields with a real medical need that offer clear additional benefits to patients and their physicians. We call this transformational medical innovation,” explains Erik Holl, Commercial Director Oncology & Hematology at Janssen-Cilag. “The success of our company is also due to our highly motivated employees, who perform incredibly well both in the office and in the field, especially now in times of COVID19!”
Janssen-Cilag relies on a diverse workforce. The company promotes the personal and professional development of its employees through various qualification programs. With flexible working time models such as part-time work, home office or job sharing as well as its own day care center for children, Janssen supports more than 800 employees in Germany in order to combine work and private life in the best possible way.
“The next wave of innovation is coming”
The future development of Janssen-Cilag, the second largest oncology company, will be characterized by three strategies, said Erik Holl: “We will focus more on targeted therapies, using molecular diagnostic and other methods to better select patients who will benefit from a targeted therapy. We will also focus more on combinations – other companies have good products! After all, we are working on the principle of using therapies earlier in patients because the results are then generally better.
Erik Holl, Commercial Director Oncology & Hematology Janssen-Cilag (right) in interview with Maria Huber, editor of PharmaBarometer, on the occasion of the award ceremony © Eurecon Verlag / Kupconcept
What counts is quality, further education and training, a broad product range and focus
The awards, which have been presented since 2000, stand for the innovative strength and sustainability of pharmaceutical companies and the progress and benefits of new drugs in the evaluation by users. For the Urologists 2020, the decisive factors in winning the “The Golden Tablet” award were the quality of the products (53%), the competence of the sales force (52%), the many innovations (39%), the range of further training and education (34%) and the research activities with a large product pipeline (20%).
Multiple awards for Janssen-Cilag
Erleada®, awarded 2020, is already the seventh Janssen-Cilag product to receive the “Most Innovative Product” award: In 2008 Invega® was honored with this award for the first time, followed by Priligy® (2010 and 2009), Zytiga® (2013, 2012), Imbruvica® (2015) and Tremfya® 2018 as well as Stelara® (2020, 2019, 2017). Janssen-Cilag received the first award “The Golden Tablet” in 2001.
Awards for Janssen-Cilag since 2000:
- The Golden Tablet (2020, 2016, 2013, 2010-2006, 2002, 2001)
- Erleada® (2020)
- Imbruvica® (2015)
- Invega® (2008)
- Priligy® (2010, 2009)
- Stelara® (2020, 2019, 2017)
- Tremfya® (2018)
- Zytiga® (2013, 2012)
About the award ceremony
Pharma Trend - Market research on innovation and sustainability
